Johanna Marines
Preclinical Development Head Mabqi
Seminars
Thursday 24th September 2026
Targeting TRPV6 with Monoclonal Antibodies to Enable Selective Ion Channel Modulation for Anti-Tumor Activity in Oncology
9:30 am
- Demonstrating the role of TRPV6 in tumor progression to validate its potential as a novel ion channel target across oncology indications
- Defining the mechanism of action of a TRPV6-targeting monoclonal antibody to establish on-target activity and functional impact on cancer cell biology
- Generating pre-clinical in vitro and in vivo efficacy data to strengthen translational confidence and support progression toward clinical development
